Xtant Medical Holdings, Inc. announced that it expects to receive $6.809897 million in funding from OrbiMed Advisors, L.L.C.
January 11, 2018
Share
Xtant Medical Holdings, Inc. (AMEX:XTNT) announced that it has entered into a material definitive agreement with OrbiMed Advisors, L.L.C. for a private placement of 945,819 common shares at a price of $7.20 per share for gross proceeds of $6,809,897 on January 11, 2018. The transaction will involve participation from returning investors, OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP funds managed by OrbiMed Advisors, L.L.C.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
XTANT MEDICAL HOLDINGS, INC. 
